Reata Pharmaceuticals Inc (RETA) Return on Equity ROE from the second quarter 2023 to second quarter 2022 and annually, average high and low, overall ranking from Jun 30 2023 to Jun 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Reata Pharmaceuticals Inc   (NASDAQ: RETA)

Reata Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Reata Pharmaceuticals Inc in the second quarter 2023?
Due to the lack of equity, it was not possible to calculate Reata Pharmaceuticals Inc 's return on equity (ROE) in its second quarter 2023

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter
Y / Y Equity Change 27.18 % - - -98.24 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -88 -354 -312 -312 -305
Return On Equity (TTM) - - -922.5 % -322.32 % -190.87 %
RETA's Total Ranking # # # # #
Equity (TTM) in Millions 87 -131 -66 5 69
Seq. Equity Change - - - -93.42 % -46.29 %
Seq. Net Income Change - - - - -

Back to RETA Management Effectiveness >> RETA's 5 Years Annual ROE >> Compare RETA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





RETA Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018
Total Equity in Millions -66 186 417 257 15
Y / Y Equity Change - -55.44 % 62.51 % 1594.42 % -
Net Income in Millions -312 -297 -248 -290 -81
Y / Y Net Income Change - - - - -
Return On Equity - -159.89 % -59.35 % -112.97 % -531.34 %

Back to RETA Management Effectiveness >> RETA's 5 Years Annual ROE >> Compare RETA ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RETA's' Return on Equity at Yahoo Finance
RETA's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RETA's Competitors
Subscribers only: Roe for Reata Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for RETA's Customers




Companies with similar Return On Equity at Jun 30 2023, within Healthcare Sector ROE
Therapeuticsmd Inc   341.13 %
Intercept Pharmaceuticals inc   248.75 %
Inhibitor Therapeutics Inc   232.75 %
Theravance Biopharma inc   220.85 %
Ir med Inc   218.43 %
Scynexis Inc   212.29 %
Protalix Biotherapeutics inc   199.41 %
Halozyme Therapeutics Inc   193.28 %
Tff Pharmaceuticals Inc  169.67 %
Waters Corporation  164.61 %
Amgen Inc   164.15 %
Omeros Corporation  140.34 %
Biomx Inc  127.82 %
Idexx Laboratories Inc  104.84 %
Davita Inc   74.49 %
Medpace Holdings Inc   72.88 %
Chimerix Inc   72.53 %
Dariohealth Corp   71.65 %
Voyager Therapeutics Inc   69.09 %

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.